Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Keros Therapeutics (KROS) Stock Price & Analysis
207 Followers
KROS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.02 - $73.00
Previous Close$48.38
Volume322.15K
Average Volume (3M)346.55K
Market Cap
$1.75B
Enterprise Value$1.32B
Total Cash (Recent Filing)$442.40M
Total Debt (Recent Filing)$14.20M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 01, 2024EPS Estimate
-$1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.14
Shares Outstanding36,083,886
10 Day Avg. Volume501,698
30 Day Avg. Volume346,552
Standard Deviation0.21
R-Squared0.08
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.69
Price to Sales (P/S)11097.59
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.63K
Enterprise Value/Gross Profit8.73K
Enterprise Value/Ebitda-11.13
Forecast
1Y Price Target
$92.17Price Target Upside89.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Keros Therapeutics News
PremiumCompany Announcements
Keros Therapeutics Announces Strategic Executive Reshuffling
PremiumPress Releases
Keros Therapeutics Announces Leadership Updates
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyElritercept continues to show clear signs of efficacy as an anemia-correcting agent in low-risk myelodysplastic syndromes.
Market OpportunityMuch unmet need in MDS and MF, and even a minority share of the market represents a meaningful opportunity.
Regulatory ApprovalPositive feedback from the FDA has been received, with alignment on the design and endpoints for a proposed Phase 3 pivotal study of elritercept in MDS.
Bears Say
Clinical TrialsThe planned Phase 2 open-label biomarker study in chronic heart failure has been terminated prior to enrolling any patients.
CompetitivenessIt will likely take more data for KER-050 to look persuasively better than luspatercept in the high unmet need subset.
Product WarningsThe label includes warnings for Winrevair related to erythrocytosis, hemoglobin increases, and severe thrombocytopenia, requiring monitoring.
---
Ownership Overview
30.18% Insiders
23.85% Mutual Funds
12.50% Other Institutional Investors
33.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $27.02 and its highest was $73.00 in the past 12 months.
What is Keros Therapeutics’s market cap?
Currently, no data Available
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 9 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on May 08, 2024. The company reported -$1.21 earnings per share for the quarter, beating the consensus estimate of -$1.333 by $0.123.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -$1.25.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 36,083,885 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.21 in its last earnings report, beating expectations of -$1.333. Following the earnings report the stock price went down -0.75%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Among the largest hedge funds holding Keros Therapeutics’s share is Woodline Partners LP. It holds Keros Therapeutics’s shares valued at 50M.
---
Keros Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.17 (89.77% Upside)
$92.17 (89.77% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 163.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.45%
12-Months-Change
Fundamentals
Return on Equity
-39.63%
Trailing 12-Months
Asset Growth
26.37%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
---
KROS Stock 12 Month Forecast
Average Price Target
$92.17
▲(89.77% Upside)
Technical Analysis
Best Analysts Covering KROS
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+11.67%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +11.67% per trade.
---